Ministry of Health

COVID-19 Vaccine Guidance

Version 1.0 September 9, 2022

Highlights of changes

- Combined the Vaccine Administration guidance and COVID-19 Vaccine Booster Recommendations guidance.
- Fall booster recommendations (page 17).
- Moderna Bivalent booster for those 18 years of age and older (pages 3, 5, 10, 16 and 31).
- Suggested intervals between previous SARS-CoV-2 infection and COVID-19 vaccination (Page 19)

This guidance provides basic information only. This document is not intended to provide or take the place of medical advice, diagnosis or treatment, or legal advice.

In the event of any conflict between this guidance document and any applicable emergency orders, or directives issued by the Minister of Health, Minister of Long-Term Care, or the Chief Medical Officer of Health (CMOH), the order or directive prevails.

- Please check the Ministry of Health (MOH) COVID-19 website regularly for updates to this document

This document can be used as a reference for vaccine clinics and vaccine administrators to support COVID-19 immunization. This document replaces the COVID-19 Vaccine Administration and COVID-19 Vaccine Third Dose and Booster Recommendations documents. Complementary resources include the individual vaccine product monographs, the COVID-19: Vaccine Storage and Handling Guidance and the COVID-19 Vaccine: Canadian Immunization Guide.

Evidence on vaccine effectiveness for COVID-19 vaccines currently authorized for use in Canada continues to evolve. For up to date information on vaccine efficacy and effectiveness, please consult the National Advisory Committee on Immunization (NACI) statements and publications on the Government of Canada webpage.
# Table of Contents

Table 1: Health Canada Authorized COVID-19 Vaccines Available for Use in Ontario........ 3
Table 2: Recommended and Minimum Intervals for COVID-19 Vaccination......................... 6
COVID-19 Vaccine Precautions & Population Specific Considerations ................................ 7
Co-Administration................................................................................................................. 9
Vaccine Product Recommendations...................................................................................... 10
Primary Series Recommendations......................................................................................... 12
Primary Series Recommendations for Moderately to Severely Immunocompromised
Individuals......................................................................................................................... 13
Booster Dose Recommendations......................................................................................... 16
Suggested Intervals Between Previous SARS-CoV-2 Infection and COVID-19 Vaccination ................................................................................................................................. 19
Adverse Events Following Immunization........................................................................... 21
Out of Province Vaccines.................................................................................................... 22
COVID-19 Vaccine Errors and Deviations......................................................................... 23
Appendix A: Pfizer-BioNTech COVID-19 Vaccine............................................................ 25
Appendix B: Moderna COVID-19 Vaccine......................................................................... 30
Appendix C: AstraZeneca COVID-19 Vaccine.................................................................... 34
Appendix D: Janssen Jcovden COVID-19 Vaccine............................................................... 36
Appendix E: Novavax COVID-19 Vaccine.......................................................................... 38
Appendix F: Medicago COVID-19 Vaccine......................................................................... 41
Appendix G: List of Immunosuppressive Medications....................................................... 43
### Table 1: Health Canada Authorized COVID-19 Vaccines Available for Use in Ontario

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Date of Authorization in Canada</th>
</tr>
</thead>
</table>
| Pfizer-BioNTech COVID-19 Vaccine | December 9, 2020 (for 16 years and older)  
May 2, 2021 (for 12 years and older)  
November 9, 2021 (first booster for 18 years and older)  
November 19, 2021 (for ages 5-11 years)  
August 19, 2022 (first booster for ages 5-11 years) |
| Moderna COVID-19 Vaccine         | December 23, 2020 (18 years and older)  
August 27, 2021 (for ages 12 and older)  
November 12, 2021 (first booster for 18 years and older)  
March 17, 2022 (for ages 6-11)  
July 14, 2022 (for ages 6 months-5 years)  
September 1, 2022 (bivalent booster for ages 18 years and older) |
| AstraZeneca COVID-19 Vaccine     | February 26, 2021 (primary series 18 years and over)  
Janssen Jcovden COVID-19 Vaccine  |
| Novavax COVID-19 Vaccine        | March 5, 2021 (primary series 18 years and over)  
Medicago COVID-19 Vaccine        | February 17, 2022 (primary series 18 years and over)  
February 24, 2022 (primary series 18 to 64 years of age) |


<table>
<thead>
<tr>
<th><strong>Type of Vaccine</strong></th>
<th><strong>Pfizer-BioNTech COVID-19 Vaccine</strong></th>
<th><strong>Moderna COVID-19 Vaccine</strong></th>
<th><strong>AstraZeneca COVID-19 Vaccine</strong></th>
<th><strong>Janssen Jcovden COVID-19 Vaccine</strong></th>
<th><strong>Novavax COVID-19 Vaccine</strong></th>
<th><strong>Medicago COVID-19 Vaccine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Potential allergen included in vaccine and/or its container</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Polyethylene glycol (PEG)&lt;sup&gt;2&lt;/sup&gt; Tromethamine (tromethanol or Tris)</td>
<td>Polyethylene glycol (PEG) Tromethamine (tromethanol or Tris)</td>
<td>Polysorbate 80&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Polysorbate 80&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Polysorbate 80&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Polysorbate 80&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>1</sup> This table identifies ingredients of the authorized, available COVID-19 vaccines that have been associated with allergic reactions in other products (NACI). This is not a complete list of substances. Any component of the COVID-19 vaccine or its container could be a potential allergen.

<sup>2</sup> Potential cross-reactive hypersensitivity between PEG and polysorbates has been reported in the literature.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Purple cap or grey cap (12 years and older, primary series and booster doses): 0.3 mL (30 mcg of mRNA)</td>
<td>Red cap for primary series for 12 years and older: 0.5 mL (100 mcg of mRNA)</td>
<td>Red cap or royal blue cap for primary series for ages 6 to 11 years: 0.25mL or 0.5mL (50 mcg of mRNA)</td>
<td>0.5 mL (5 x 10^{10} viral particles)</td>
<td>0.5 mL (5 x 10^{10} viral particles)</td>
<td>0.5 mL (5 mcg of recombinant protein)</td>
<td>0.5 mL (3.75 mcg SARS-CoV-2 recombinant spike protein)</td>
</tr>
<tr>
<td>Orange cap (5 to 11 years, primary series and booster doses): 0.2mL (10 mcg of mRNA)</td>
<td>Red cap or royal blue cap for primary series for 6 months to 5 years: 0.25 mL (25 mcg of mRNA)</td>
<td>Royal blue cap for primary series for 6 months to 5 years: 0.25 mL (25 mcg of mRNA)</td>
<td>0.5 mL (5 x 10^{10} viral particles)</td>
<td>0.5 mL (5 x 10^{10} viral particles)</td>
<td>0.5 mL (5 mcg of recombinant protein)</td>
<td>0.5 mL (3.75 mcg SARS-CoV-2 recombinant spike protein)</td>
</tr>
<tr>
<td>Red cap or royal blue cap for booster dose(s) for 18 years and older: 0.25mL or 0.5mL (50 mcg of mRNA)</td>
<td>Bivalent booster: Royal blue cap for booster dose(s) for 18 years and older: 0.5 mL (50 mcg of mRNA, 25 mcg ancestral strain and 25 mcg omicron BA.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


### Table 2: Recommended and Minimum Intervals for COVID-19 Vaccination

<table>
<thead>
<tr>
<th>Age</th>
<th>Recommended Intervals</th>
<th>Minimum Intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months to under 5 years (Moderna)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Series</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 2nd dose, 2 months (56 days) after 1st dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Booster Doses</strong> - not eligible</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 years and older (Pfizer) or 6 years and older (Moderna)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Series</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 2nd dose, 2 months (56 days) after 1st dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Booster Doses</strong>: 6 months (168 days) after last dose (Pfizer only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderately or severely immuno-compromised individuals ≥6 months of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Series</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 2nd dose, 2 months (56 days) after 1st dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3rd dose, 2 months (56 days) after 2nd dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Booster Doses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• (≤4 years old) – not eligible</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• (≥5 years old) – 6 months (168 days) after last dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

3 There is good evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness and may be associated with a lower risk of myocarditis and/or pericarditis in adolescents and young adults. See the Canadian Immunization Guide for more information.

4 NACI’s Minimum Interval Recommendation (Table 1: Immunization schedule for a primary series, by COVID-19 vaccine).
COVID-19 Vaccine Precautions & Population Specific Considerations

See the COVID-19 Vaccine: Canadian Immunization Guide’s section on Contraindications and Precautions for recommendations for individuals with allergies or severe immediate allergic reactions to a COVID-19 vaccine, bleeding disorders, immune thrombocytopenia, venous thromboembolism, thrombosis with thrombocytopenia syndrome, myocarditis and/or pericarditis following vaccination, Guillain-Barré syndrome and Bell’s palsy.

People who experienced a severe immediate allergic reaction after a dose of an mRNA COVID-19 vaccine can safely receive future doses of the same or another mRNA COVID-19 vaccine after consulting with an allergist/immunologist or another appropriate physician. See the CIG for more information.

Individuals with known allergies to components of the vaccines may speak with an appropriate physician or nurse practitioner (NP) for evaluation. This assessment will enable the development of a vaccination care plan which may include receiving the vaccine under the supervision of your physician. Documentation of the discussion with the physician/NP may be provided to the immunizing clinic and can include a vaccination care plan (including what types of parameters the clinic should meet to provide safe vaccination administration, such as availability of advanced medical care to manage anaphylaxis), details/severity of the previous allergic episode(s), confirm that appropriate counselling on the safe administration of vaccine was provided, and include the date, the clinician’s name, signature and contact information as well as the individual’s name and date of birth.

**History of fainting/ dizziness, or fear of injections/ needles**

Individuals with a history of fainting/dizziness, or fear of injections/needles can safely receive the COVID-19 vaccine. Considerations may include:

- Immunize while seated to reduce injuries due to fainting.
- If considered high-risk, immunize while lying down.
- These individuals may bring a support person.
- See CARD resources to support immunization
Breastfeeding or Pregnant

Pregnant and breastfeeding individuals should receive all recommended doses of a COVID-19 vaccine (including booster doses) as soon as they become eligible. See the Provincial Council for Maternal and Child Health’s decision making tool, the Society of Obstetricians and Gynaecologists of Canada Statement on COVID-19 Vaccination in Pregnancy and the Canadian Immunization Guide for more information.

Autoimmune Conditions or Immunocompromised due to disease or treatment

It is recommended that all moderately to severely immunocompromised individuals receive a 3-dose primary series of a COVID-19 vaccine. These individuals are encouraged to speak with their treating health care provider regarding the timing of vaccination in relation to therapy for their underlying health condition and/or treatment modification in view of possible decreased vaccine effectiveness with the use of immunosuppressive therapy. See the COVID-19 Vaccine: Canadian Immunization Guide’s section on immunocompromised persons for more information.

It is recommended that re-vaccination with a new COVID-19 vaccine primary series be initiated post-transplantation for hematopoietic stem cell transplant (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy given the loss of immunity following therapy or transplant. Optimal timing for re-immunization should be determined on a case-by-case basis in consultation with the clinical team. For additional information on organ transplantation, consult the Canadian Society of Transplantation statement on COVID-19 vaccination.

- For additional information on rheumatic diseases, consult the Canadian Rheumatology Association statement on COVID-19 vaccination.
- For additional information on inflammatory bowel disease, consult the Canadian Association of Gastroenterology statement on COVID-19 vaccination.

---

5 As per the Canadian Immunization Guide, HSCT recipients should be viewed as vaccine naïve (i.e. never immunized) and require re-immunization after transplant.
• For additional information on immunodeficiency conditions, consult the COVID-19 resources on the Canadian Society of Allergy and Clinical Immunology webpage.

• For frequently asked questions about COVID-19 vaccine and adult cancer patients, consult Cancer Care Ontario.

**Symptoms, either current or displayed recently, of chest pain or shortness of breath**

• Vaccine should not be offered to persons displaying current or recent history of chest pain or shortness of breath.

• Persons displaying current or recent history of chest pain or shortness of breath should consult with a health care provider prior to vaccination and/or if symptoms are severe, should be directed to the emergency department or instructed to call 911.

**Co-Administration**

NACI recommends that for individuals 5 years of age and older, COVID-19 vaccines may be given simultaneously with (i.e., same day), or at any time before or after non-COVID-19 vaccines (including live and non-live vaccines). Informed consent should include a discussion of the benefits and risks given the limited data available on administration of COVID-19 vaccines at the same time as, or shortly before or after, other vaccines.

At this time, Moderna (25 mcg) COVID-19 vaccine, for ages 6 months to 5 years, should not be given concurrently (i.e., same day) with other vaccines but rather wait for a period of 14 days before or after administration of other vaccines. This could prevent erroneous attribution of an adverse event to one particular vaccine or the other. A shorter interval between the administration of Moderna (25 mcg) vaccine and a different vaccine may be warranted in some circumstances at the discretion of a health care provider.

Studies to assess safety and immunogenicity of concurrent administration of COVID-19 vaccines with other vaccines are ongoing.
Vaccine Product Recommendations

For a primary series

1. NACI continues to preferentially recommend that a complete primary series of a monovalent (original) mRNA COVID-19 vaccine (i.e., Pfizer-BioNTech, Moderna) should be offered to individuals in the authorized age group without contraindications to the vaccine.

2. Novavax or Medicago may be offered to individuals in the authorized age group without contraindications to the vaccine who are not able or willing to receive an mRNA COVID-19 vaccine.

3. A complete primary series of a viral vector Janssen COVID-19 vaccine may be offered to individuals in the authorized age group without contraindications to the vaccine only when all other authorized COVID-19 vaccines are contraindicated.

For booster doses

1. For individuals who are recommended to receive a fall booster dose, NACI recommends that the authorized dose of a bivalent Omicron-containing mRNA COVID-19 vaccine should be offered. If the bivalent Omicron-containing mRNA COVID-19 vaccine is not readily available, an original mRNA COVID-19 vaccine should be offered to ensure timely protection.
   - For children 5-11 years of age, the only authorized vaccine for the first booster dose is monovalent Pfizer (10 mcg).
   - For adolescents 12-17 years of age with moderately to severely immunocompromising conditions, a booster dose of the bivalent Moderna COVID-19 vaccine may be offered off-label based on clinical discretion.

2. Novavax may be offered to individuals in the authorized age group without contraindications to the vaccine who are not able or willing to receive an mRNA COVID-19 vaccine.

3. A booster dose of a viral vector Janssen COVID-19 vaccine should only be offered when all other Health Canada authorized COVID-19 vaccines are contraindicated.

Effectiveness against infection and COVID-19 disease decreases with time. As such, booster doses are recommended for eligible individuals to obtain stronger protection. As per the Canadian Immunization Guide (CIG), the intent of a booster dose is to restore immune protection that may have decreased over time to a level
that is no longer deemed sufficient in individuals who initially responded adequately to a complete primary vaccine series.

**Individuals are recommended to receive an mRNA vaccine for their primary series and booster dose(s),** due to the strong protection offered and well-established safety and effectiveness data ([CIG, 2022](#)). Evidence from clinical trials suggests that booster doses of mRNA vaccines given 6 months after the primary series elicit a robust immune response. Real world data suggests that a booster dose provides good short-term vaccine effectiveness and has a safety profile similar to the second dose of the COVID-19 vaccine. Emerging evidence suggests that vaccine effectiveness against infection/symptomatic disease for Omicron from a first booster of mRNA vaccine decreases over time since vaccination ([NACI, 2022](#)). Serological testing is not recommended before or after COVID-19 vaccination ([CIG, 2022](#)). See the [CIG](#) for more information on the evidence, safety and immunogenicity of COVID-19 booster doses.

The evidence on the risk of myocarditis/pericarditis after a booster dose of an mRNA vaccine is limited, but appears to be lower than the already rare risk after the second dose of the primary series but higher than after the first dose ([NACI, 2021](#)). Information for subsequent immunization in individuals who experienced myocarditis (with or without pericarditis) within 6 weeks of receiving a previous dose of an mRNA COVID-19 vaccine is available in the [COVID-19 Vaccine Chapter of the CIG](#).

**Booster dose(s) of Novavax may be offered to individuals without contraindications who are not able or willing to receive an mRNA vaccine.** As part of informed consent, individuals who are not able or willing to receive an mRNA vaccine should be made aware of the long-term effectiveness and safety data that is available for the mRNA vaccine products as compared to the other authorized COVID-19 vaccines and that this vaccine is not currently authorized for use as a booster dose in Canada ([CIG, 2022](#)).

**Booster dose(s) of a viral vector vaccine should only be offered when all other Health Canada authorized COVID-19 vaccines are contraindicated.** Informed consent for a viral vector vaccine should include discussion about the increased risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), Capillary Leak Syndrome (CLS), and Guillain-Barre syndrome (GBS) following viral vector COVID-19 vaccines and the very limited evidence on the use and effectiveness of an additional dose of viral vector COVID-19 vaccine ([CIG, 2021](#)).
The Medicago COVID-19 vaccine is not currently authorized for use as booster dose(s) in Canada. Informed consent when administering a Medicago primary series should include mention that this vaccine is not currently authorized for use as a booster dose in Canada. There are no data available on the use of Medicago as a booster dose, following either a homologous or heterologous schedule (CIG, 2022). NACI will assess evidence on the use of Medicago vaccine as a booster dose as information becomes available and provide additional guidance as needed.

The National Advisory Committee on Immunization (NACI), the Ontario Immunization Advisory Committee (OIAC), the Ministry of Health (MOH), and Public Health Ontario (PHO) are closely following the research on the safety and effectiveness of additional doses. Recommendations will be re-examined on an ongoing basis as new data emerges and any updates will be issued as part of Ontario’s ongoing COVID-19 vaccination program as further evidence becomes available.

**Primary Series Recommendations**

The recommended interval between primary series doses is 2 months (56 days). There is good evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness and may be associated with a lower risk of myocarditis and/or pericarditis in adolescents and young adults. See the Canadian Immunization Guide for more information.

Where a different vaccine product is used to complete the two-dose primary vaccine series, the second dose should be given at a recommended dose interval of 2 months (56 days). If AstraZeneca was given as the first dose, the second dose can be given at a recommended interval of at least 2 months (56 days). If using the Health Canada authorized interval between first and second doses, the interval of the vaccine product used for the first dose should be followed. There is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in a more robust and durable immune response and higher vaccine effectiveness (NACI). The decision to use the longer recommended dose interval should consider biological and social risk factors for exposure (e.g., local epidemiology, circulation of VOCs, living settings) and severe disease. These intervals are a guide and clinical discretion is advised.
Primary Series Recommendations for Moderately to Severely Immunocompromised Individuals

Rationale

• A 3-dose primary series is recommended for certain moderately to severely immunocompromised individuals with the aim of enhancing the immune response and establishing an adequate level of protection for individuals who may develop no or a sub-optimal immune response to a 2-dose primary series. See the COVID-19 chapter in the Canadian Immunization Guide: Immunocompromised persons for more information.

• There is emerging evidence on the safety and immunogenicity following a third dose of a COVID-19 vaccine for those that have not seroconverted following their second dose in select immunocompromised populations.

Recommendations

• A 3-dose primary series of mRNA COVID-19 vaccines is recommended for the following populations eligible for vaccination with the vaccine product authorized for their age group
  
  o Individuals receiving dialysis (hemodialysis or peritoneal dialysis)
  
  o Recipients of solid-organ transplant and taking immunosuppressive therapy
  
  o Individuals receiving active treatment6 (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
  
  o Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)

---

6 Active treatment includes patients who have completed treatment within 3 months. Active treatment is defined as chemotherapy, targeted therapies, immunotherapy, and excludes individuals receiving therapy that does not suppress the immune system (e.g., solely hormonal therapy or radiation therapy). See Ontario Health/Cancer Care Ontario’s Frequently Asked Questions for more information.
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- HIV with AIDS-defining illness in last 12 months before starting vaccine series, or severe immune compromise with CD4 count <200 cells/uL or CD4 percentage <15%, or without HIV viral suppression
- Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies\(^7\) (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the Canadian Immunization Guide for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive (See Appendix G).

- Moderately to severely immunocompromised children ages 5-11 years should be immunized with a primary series of three doses of Pfizer-BioNTech COVID-19 vaccine (10mcg). Indirect data from adult populations (≥18 years of age) suggests Moderna (100 mcg) may result in higher vaccine effectiveness after a 2-dose primary series compared to Pfizer-BioNTech (30 mcg) and is associated with a higher seroconversion rate among adult immunocompromised patients (NACI, 2022). Given this potential benefit, administration of the Monovalent Moderna (50 mcg) vaccine as a 3-dose primary series may be considered for some immunocompromised individuals 6 to 11 years of age.
- Immunocompromised individuals 12 years of age and older should be offered the full dose of either Moderna (100 mcg) or Pfizer-BioNTech (30 mcg) as a 3-dose primary series.
- Immunocompromised individuals between the ages of 12-29 are preferentially recommended to receive Pfizer-BioNTech (30 mcg) but may receive Moderna (100 mcg) based on clinical discretion.

---
\(^7\) Active treatment for patients receiving B-cell depleting therapy includes patients who have completed treatment within 12 months.
- The safety and efficacy of Novavax have not been established in individuals who are immunocompromised due to disease or treatment. Informed consent for use of the vaccine in this population (as a 3-dose primary series or booster dose(s)) should include discussion that there is currently limited evidence on the use of Novavax in this population, while there is evidence on the safety profile and effectiveness of mRNA COVID-19 vaccines in these populations based on real world use with large numbers of individuals (CIG, 2022).

- The recommended interval between the second dose and the third dose of the primary series is at least **2 months (56 days)**.
  - As per NACI, the minimum interval is 28 days; however, an interval longer than the minimum of 28 days between doses is likely to result in a better immune response.
  - Exact timing should be decided with the treating provider to optimize the immune response from the vaccine series and minimize delays in management of the individual’s underlying condition. Additionally, the interval should consider risk factors for exposure (including local epidemiology and circulation of variants of concern) and risk of severe disease from SARS-CoV-2 infection. Some immunocompromised individuals may still be susceptible after the 1st or 2nd dose in the primary series, so their period of susceptibility until receipt of the additional dose will also increase if the interval between doses is increased.

- For guidance on the timing of vaccine administration for transplant recipients and those requiring immunosuppressive therapies, a more comprehensive list of conditions leading to primary immunodeficiency, and for further information on immunosuppressive therapies, refer to Immunization of Immunocompromised Persons in the Canadian Immunization Guide (CIG), Part 3 – Vaccination of Specific Populations.

- To protect those who are immunocompromised, it also is strongly recommended that all people that come into close contact (e.g., healthcare workers and other support staff, family, friends, caregivers) with these individuals stay up to date with their COVID-19 vaccines by receiving all recommended doses. Immunocompromised individuals and those that come into close contact with them should also continue to follow recommended public health measures for prevention and control of SARS-CoV-2 infection and transmission.
## Booster Dose Recommendations

### Table 3: Recommended COVID-19 Vaccine Booster Dose(s) in Certain Populations

<table>
<thead>
<tr>
<th>Population</th>
<th>Vaccine type (and dose) which may be preferred</th>
<th>Rationale or additional considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 to 11 years of age (including those moderately to severely immunocompromised)</td>
<td>Monovalent Pfizer-BioNTech (10 mcg) is recommended.</td>
<td>Monovalent Pfizer-BioNTech (10 mcg) is the only authorized booster for this population. Children in this age group who are at high risk of severe illness due to COVID-19 are recommended to receive a booster dose.</td>
</tr>
<tr>
<td>12 to 17 years of age (including those moderately to severely immunocompromised)</td>
<td>Bivalent Moderna (50 mcg) may be offered off-label to those who are moderately to severely immunocompromised. Monovalent Pfizer-BioNTech (30 mcg) is recommended over monovalent Moderna (50 mcg) for individuals that are immunocompetent.</td>
<td>Lower reported rates of myocarditis/pericarditis following vaccination with monovalent Pfizer-BioNTech (30 mcg) compared to monovalent Moderna (50 mcg) in this age group.</td>
</tr>
<tr>
<td>18-69 years of age (including those moderately to severely immunocompromised)</td>
<td>Bivalent Moderna (50 mcg) is preferred over monovalent Pfizer-BioNTech (30 mcg) and monovalent Moderna (50 mcg).</td>
<td>Bivalent Moderna (50 mcg) elicited higher (superior) neutralizing antibody responses against the original strain, Omicron BA.1, and Omicron BA.4/BA.5 among participants with and without prior infection, compared to monovalent Moderna (50 mcg). This effect was consistent across age groups, 18-65 years of age and &gt;65 years of age. The BA.1- targeted, bivalent mRNA vaccines may also elicit a greater breadth of immune response, potentially providing additional protection against future variants of concern, although given the unpredictable nature of the ongoing evolution of SARS-CoV-2, this is uncertain at this time.</td>
</tr>
<tr>
<td>Population</td>
<td>Vaccine type (and dose) which may be preferred</td>
<td>Rationale or additional considerations</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>≥70 years of age (including those moderately to severely immunocompromised)</td>
<td>For individuals 70 years of age and older; residents of long-term care homes, retirement homes or individuals in other congregate settings. bivalent Moderna (50 mcg) is preferred. If bivalent Moderna (50 mcg) vaccine is not available, the monovalent Moderna (100 mcg) may be preferred over other vaccines based on clinical discretion.</td>
<td>Monovalent Moderna (100 mcg) induces somewhat higher antibody levels compared to monovalent Pfizer-BioNTech (30 mcg). Protection (against severe disease) from a primary series with monovalent Moderna (100 mcg) may be more durable than monovalent Pfizer BioNTech (30 mcg). These populations may have less robust immune function (some older adults) or a diminished immune response to the vaccine (some immunocompromised individuals). It is possible that monovalent Moderna (100 mcg) may induce a better immune response than monovalent Moderna (50 mcg). Currently there are no data comparing the immune responses after a booster vaccination with bivalent Moderna (50 mcg), monovalent Moderna (100 mcg) and monovalent Pfizer-BioNTech (30 mcg) in these populations.</td>
</tr>
</tbody>
</table>

**Fall Booster Doses**

Booster dose(s) are recommended based on the ongoing risk of infection due to waning immunity, the ongoing risk of severe illness from COVID-19, the societal disruption that results from transmission of infections, and the adverse impacts on health system capacity from the COVID-19 pandemic.

- All individuals in Ontario aged 5-11 years are eligible to receive a booster dose of Pfizer-BioNTech (10 mcg) vaccine after completion of a primary COVID-19 vaccine series. Children 5-11 years with underlying medical conditions are at increased risk for severe outcomes and are recommended to receive a booster dose. This may include children who are medically fragile and/or have medical complexities, have more than one comorbidity or have immunocompromising conditions.
• As of September 12, 2022, the following high-risk groups will be recommended to receive their fall COVID-19 bivalent (Moderna) booster dose, regardless of the number of booster doses previously received:
  - Residents of long-term care homes, retirement homes, Elder Care Lodges, and individuals living in other congregate settings that provide assisted-living and health services
  - Individuals aged 70 years and older
  - Individuals who are 12 years and older with moderately to severely immunocompromising conditions
    - For adolescents 12-17 years of age with moderately to severely immunocompromising conditions, a booster dose of the bivalent Moderna COVID-19 vaccine may be offered off-label based on clinical discretion.
  - Adults 18 years and older who identify as First Nations, Inuit or Métis and their non-Indigenous household members aged 18 years and older
  - Pregnant individuals aged 18 years and older
  - Health care workers aged 18 years and older

• As of September 26, 2022, all individuals aged 18 years and older will be eligible to receive a fall COVID-19 bivalent (Moderna) booster dose, regardless of the number of booster doses previously received.

While NACI recommends that the authorized dose of a bivalent Omicron-containing mRNA COVID-19 vaccine should be offered as a booster dose to the authorized age group (≥18 years of age), if the bivalent Omicron-containing mRNA COVID-19 vaccine is not readily available, an original mRNA COVID-19 vaccine should be offered to ensure timely protection.

• It is recommended that COVID-19 booster doses be offered at an interval of 6 months (168 days) after a previous COVID-19 vaccine.
Suggested Intervals Between Previous SARS-CoV-2 Infection and COVID-19 Vaccination

The Ontario Ministry of Health, in alignment with NACI, continues to recommend that COVID-19 vaccines should be offered to individuals with previous SARS-CoV-2 infection without contraindications to the vaccine. Below are suggested intervals between previous SARS-CoV-2 infection and COVID-19 vaccination.

<table>
<thead>
<tr>
<th>Infection timing relative to COVID-19 vaccination</th>
<th>Population</th>
<th>Suggested interval between infection* and vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection prior to completion or initiation of primary vaccination series</td>
<td>Individuals 6 months of age and older who are not considered moderately to severely immunocompromised and with no previous history of multisystem inflammatory syndrome in children (MIS-C)</td>
<td>Receive the vaccine 2 months (56 days) after symptom onset or positive test (if asymptomatic)</td>
</tr>
<tr>
<td></td>
<td>Individuals 6 months of age and older who are moderately to severely immunocompromised and with no previous history of MIS-C</td>
<td>Receive the vaccine dose 1 to 2 months (28 to 56 days) after symptom onset or positive test (if asymptomatic)</td>
</tr>
<tr>
<td></td>
<td>Individuals 6 months of age and older with a previous history of MIS-C (regardless of immunocompromised status)</td>
<td>Receive the vaccine dose when clinical recovery has been achieved or ≥90 days since the onset of MIS-C, whichever is longer</td>
</tr>
</tbody>
</table>
Infection timing relative to COVID-19 vaccination

<table>
<thead>
<tr>
<th>Population</th>
<th>Suggested interval between infection* and vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection after primary series Individuals currently eligible for booster dose(s)</td>
<td>A minimum of 3 months (84 days) after symptom onset or positive test (if asymptomatic); however, a 6 month (168 day) interval may provide better immune response regardless of the product given.</td>
</tr>
</tbody>
</table>

*A previous infection with SARS-CoV-2 is defined as:

- Confirmed by a molecular (e.g., PCR) or rapid antigen test; or
- Symptomatic AND a household contact of a confirmed COVID-19 case.

These suggested intervals are based on immunological principles and expert opinion, and may change as evidence on COVID-19, variants of concern (VOCs), and COVID-19 vaccines emerge. When considering whether or not to administer vaccine doses following the suggested intervals outlined in this table, biological and social risk factors for exposure (e.g., local epidemiology, circulation of VOCs, living settings) and severe disease should also be taken into account. These intervals are a guide and clinical discretion is advised.

Before vaccination, the individual should no longer be considered infectious, symptoms of acute illness should be completely resolved, and their isolation period must be completed. These suggested waiting times are intended to minimize the risk of transmission of COVID-19 at an immunization venue and to enable monitoring for COVID-19 vaccine adverse events without potential confounding from symptoms of COVID-19 or other co-existing illnesses.

A longer interval between infection and vaccination may result in a better immune response as this allows time for the immune response to mature in breadth and strength, and for circulating antibodies to decrease, thus avoiding immune interference when the vaccine is administered.
Adverse Events Following Immunization

All health care providers administering vaccines must be familiar with the anaphylaxis protocols for their clinic sites and ensure availability of anaphylaxis management kits. For additional information please visit the Public Health Ontario resource on the Management of Anaphylaxis Following Immunization in the Community and the Canadian Immunization Guide.

Those administering vaccines should ensure that vaccine recipients or their parents/guardians are advised to notify clinic staff, or if they have left the clinic, call their doctor/nurse practitioner or go to the nearest hospital emergency department if they develop any of the following symptoms:

- Hives
- Swelling of the face, throat or mouth
- Altered level of consciousness/serious drowsiness
- Trouble breathing, hoarseness or wheezing
- High fever (over 40°C or 104°F)
- Convulsions or seizures
- Other serious reactions (e.g., “pins and needles” or numbness)

A reduced post-vaccination observation period, between 5 - 15 minutes may be considered for the administration of booster dose(s) of COVID-19 vaccine during the pandemic, if specific conditions are met such as the client’s past experience with COVID-19 vaccine doses and other relevant conditions as outlined in the NACI 2020-2021 influenza vaccine advice. This would be an exception to usual immunization guidance and this approach could be used in specific settings (i.e., mass immunization clinic, primary care clinics, pharmacies) at this time on a temporary basis, weighing the risks of a reduction in observation period (e.g., small increased risk of delayed identification of an adverse event that may require immediate medical attention) and reducing risk of SARS-CoV-2 transmission where physical distancing cannot be maintained and allowing more individuals to be immunized in a given time period.
Guidance on reporting adverse events following immunization (AEFI) for health care providers

- Health care providers administering vaccines are required to inform vaccine recipients or their parent/guardian of the importance of reporting adverse events following immunization (AEFIs) to a health care provider in accordance with Section 38 of the Health Protection and Promotion Act (HPPA). Vaccine recipients or their parent/guardian may also contact their local public health unit to ask questions or to report an AEFI.
- Specified health care providers (e.g., physicians, nurses and pharmacists) are required under s.38(3) of the HPPA to report AEFIs to their local public health unit. Reports should be made using the Ontario AEFI Reporting Form.
- See Public Health Ontario’s vaccine safety webpage and Fact Sheet - Adverse Event Following Immunization Reporting For Health Care Providers In Ontario for additional guidance.
- The Ontario Ministry of Health in collaboration with Public Health Ontario monitors reports of AEFIs. This monitoring is done in collaboration with the Public Health Agency of Canada and Health Canada.

Out of Province Vaccines

For guidance on managing and documenting individuals who have received COVID-19 vaccines outside of Ontario, please consult the Government of Canada’s COVID-19: Recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study.

Individuals who have received COVID-19 vaccines outside of Ontario or Canada should contact their local public health unit to have their COVID-19 immunization record documented in COVaxON.

Proof of immunization (e.g., an immunization record, proof of vaccination certificate (PVC)) is required to verify the COVID-19 vaccine product received out of province. PHUs are responsible for documenting immunization information for individuals who have received COVID-19 vaccine doses outside of Ontario into COVaxON. See the COVaxON job aid and functionality change communications for more information.

---

8 See Canadian Immunization Guide to Immunization records.
9 The Canadian Immunization Guide outlines that vaccination should only be considered valid if there is written documentation of vaccine administration.
COVID-19 Vaccine Errors and Deviations


For inadvertent immunization errors and deviations that are not addressed in the Government of Canada’s guidance and/or that involve multiple errors or have additional complexity, health care providers are encouraged to contact their local public health unit (PHU) for further advice.

The local PHU should be notified, and vaccine administration errors or deviations should be handled and reported in accordance with both the site (if non-PHU) and PHU procedures.

- Vaccine administration errors and deviations that should be escalated to the Ministry of Health include those that may result in public safety concerns, cause misinformation, serious adverse events or death to any person; where large volumes of vaccine doses have been impacted or wasted; or where there is inadvertent administration of exposed and/or expired vaccine to a large number of patients. When in doubt, err on the side of caution and notify the Ministry of Health. For all issues that are escalated to the Ministry of Health, please report these per the following protocol: Email the Ministry of Health Communications team (media.moh@ontario.ca) and the Implementation team (covid.immunization@ontario.ca), with the following header:

- Incident Report for [PHU/Site] on [Date]:
  - Description of Incident
  - Date of Incident:
  - Location of Incident:
  - Type of Incident:
  - Administration error or deviation:
  - Description of Incident:
  - Summary of action and steps taken to-date:
  - Next steps:
If an inadvertent vaccine administration error or deviation results in an adverse event following immunization (AEFI), complete Ontario’s AEFI reporting form, including details of the error or deviation. The completed AEFI form should be submitted to your local PHU.
Appendix A: Pfizer-BioNTech COVID-19 Vaccine

Considerations for Administration

In alignment with NACI’s recommendation, the Ministry of Health has made a preferential recommendation for the use of Pfizer-BioNTech COVID-19 vaccine for individuals 5-29 years of age if receiving a primary series dose, or 5-17 years of age if receiving a booster dose. This recommendation stems from an observed increase in the number of reports of myocarditis/pericarditis following vaccination with Moderna relative to Pfizer-BioNTech in adolescents and young adults, particularly among males, in Ontario, Canada, and internationally.

Children 5 to 11 years of age should receive the 10 mcg dose of the Pfizer-BioNTech vaccine (orange cap), whereas adolescents 12 years of age and older should receive the 30 mcg dose of the Pfizer-BioNTech vaccine (purple cap or grey cap).

Children who receive the 10 mcg Pfizer-BioNTech COVID-19 vaccine for their first dose and who have turned 12 years of age by the time the second dose is due may receive the 30 mcg Pfizer-BioNTech COVID-19 vaccine that is authorized for individuals ages 12 and older to complete their primary series. If the second dose of 10 mcg is given, the dose should still be considered valid and the series complete.

Warnings & Precautions

Myocarditis & Pericarditis

There have been Canadian and international reports of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines. Global experience to date has indicated that the majority of reported cases have responded well to conservative therapy (rest, treatment with non-steroidal anti-inflammatory drugs (NSAIDS)) and tend to recover quickly. Symptoms have typically been reported to start within one week after vaccination. Cases of myocarditis/pericarditis following COVID-19 mRNA vaccination occur more commonly in adolescents and young adults (12 to 29 years of age), more often after the second dose and more often in males than females. It is unknown if and/or to what extent myocarditis/pericarditis will occur in children 5 to 11 years old following immunization with the 10 mcg dose of the Pfizer-BioNTech vaccine. Safety surveillance data from the US suggests that the risk of myocarditis or pericarditis may be lower in children aged 5 to 11 years following Pfizer-BioNTech (10 mcg) vaccination compared to adolescents and young adults (who receive a 30 mcg Pfizer-BioNTech dose). Among children 5 to 11 years of age, very rare cases were most often reported following dose 2 and among males. Post-market safety
surveillance is ongoing (NACI, 2022). Providers are encouraged to consult the enhanced epidemiologic surveillance summary from Public Health Ontario for trends and risk of myocarditis/pericarditis following mRNA vaccines in Ontario. NACI continues to strongly recommend that a complete series with an mRNA COVID-19 vaccine be offered to all eligible individuals in Canada, including those 5 years of age and older, in the authorized age group without contraindications to the vaccine.

The benefits of vaccination with COVID-19 vaccines continue to outweigh the risks of COVID-19 illness and related, possibly severe outcomes for all age groups.

- Anyone receiving an authorized mRNA COVID-19 vaccine should be informed of the risk of myocarditis and pericarditis, and advised to seek medical attention if they develop symptoms including chest pain, shortness of breath, palpitations (pounding or heart racing), or feeling of rapid or abnormal heart rhythm (NACI).

In most circumstances, and as a precautionary measure until more information is available, individuals with a diagnosed episode of myocarditis (with or without pericarditis) within 6 weeks of receipt of a previous dose of an mRNA COVID-19 vaccine should defer further doses of the vaccine. This includes any person who had an abnormal cardiac investigation including electrocardiogram (ECG), elevated troponins, echocardiogram or cardiac MRI after a dose of an mRNA vaccine. This is a precaution based on recommendations issued by the National Advisory Committee on Immunization (NACI) in the Canadian Immunization Guide. NACI, Public Health Ontario (PHO), and the Ontario Ministry of Health (MOH) are following this closely and will update this recommendation as more evidence becomes available.

- In situations where there is uncertainty regarding myocarditis diagnosis, discussion should occur with an appropriate physician or nurse practitioner on potential options for (re)immunization with the same or alternative COVID-19 vaccine, including a risk-benefit analysis for the individual. Those with a history compatible with pericarditis and who either had no cardiac workup or had normal cardiac investigations, can receive the next dose once they are symptom free and at least 90 days has passed since vaccination.

- Some people with confirmed myocarditis with or without pericarditis may choose to receive another dose of vaccine after discussing the risks and benefits with their health care provider. Individuals can be offered the next dose once they are symptom free and at least 90 days has passed since vaccination.
If another dose of vaccine is offered, they should be offered the Pfizer-BioNTech 30 mcg vaccine due to the lower reported rate of myocarditis and/or pericarditis following the Pfizer-BioNTech 30 mcg vaccine compared to the Moderna 100 mcg vaccine. Informed consent should include discussion about the unknown risk of recurrence of myocarditis and/or pericarditis following receipt of additional doses of Pfizer-BioNTech COVID-19 vaccine in individuals with a history of confirmed myocarditis and/or pericarditis after a previous dose of mRNA COVID-19 vaccine, as well as the need to seek immediate medical assessment and care should symptoms develop.


Interim clinical guidance and an algorithm for the identification and management of myocarditis and pericarditis following mRNA COVID-19 vaccination in children is available from the Hospital for Sick Children.

A clinical framework is also available from the Canadian Journal of Cardiology [Myocarditis and Pericarditis following COVID-19 mRNA Vaccination: Practice Considerations for Care Providers](https://www.circscanada.ca/article/doi/10.1007/s12560-021-02173-0)

### Multi-Inflammatory Syndrome in Children or in Adults (MIS-C/A) following vaccination with an mRNA COVID-19 vaccine

Children and adolescents with SARS-CoV-2 infection are at risk of multisystem inflammatory syndrome in children (MIS-C), a rare but serious syndrome that can occur several weeks following SARS-CoV-2 infection. Very rare cases of MIS-C/A (multisystem inflammatory syndrome in children and in adults) have been reported following vaccination with COVID-19 mRNA vaccines in Canada and internationally among individuals aged 12 years and older. However, on October 29, 2021, the European Medical Association Pharmacovigilance Risk Assessment Committee (EMA-PRAC) issued a statement that there is currently insufficient evidence on a possible link between mRNA COVID-19 vaccines and very rare cases of MIS-C/A.

For children with a previous history of MIS-C unrelated to any previous COVID-19 vaccination, vaccination should be postponed until clinical recovery has been achieved or until it has been ≥ 90 days since diagnosis, whichever is longer.
Bell's palsy following vaccination with an mRNA COVID-19 vaccine

Very rare cases of Bell's palsy (typically temporary weakness or paralysis on one side of the face) have been reported following vaccination with COVID-19 mRNA vaccines (Pfizer-BioNTech or Moderna) in Canada and internationally among individuals aged 12 years and older. Bell's palsy is an episode of facial muscle weakness or paralysis. The condition is typically temporary. Symptoms appear suddenly and generally start to improve after a few weeks. The exact cause is unknown. It’s believed to be the result of swelling and inflammation of the nerve that controls muscles on the face.

Symptoms of Bell's palsy may include:

- uncoordinated movement of the muscles that control facial expressions, such as smiling, squinting, blinking or closing the eyelid
- loss of feeling in the face
- headache
- tearing from the eye
- drooling
- lost sense of taste on the front two-thirds of the tongue
- hypersensitivity to sound in the one ear
- inability to close an eye on one side of the face

Individuals should seek medical attention if they develop symptoms of Bell’s palsy following receipt of mRNA COVID-19 vaccines. Health care providers should consider Bell’s palsy in their evaluation if the patient presents with clinically compatible symptoms after an mRNA COVID-19 vaccine. Investigations should exclude other potential causes of facial paralysis.

Allergies

See the COVID-19 Vaccine: Canadian Immunization Guide for information on vaccination for all individuals with allergies (including those with allergic reactions to previous doses of any COVID-19 vaccine, or vaccine components).

Side effects

The Pfizer-BioNTech COVID-19 vaccine, like medicines and other vaccines, may cause side effects. In clinical trials, most of the side effects experienced were mild to moderate, and usually resolved within a few days. Please see the product monograph for a complete list of reported side effects.
Vaccine Preparation & Administration

See the Pfizer-BioNTech product monograph for step-by-step directions for administration (vial and dose verification, thawing prior to dilution, dilution, preparation) and information on packaging types and expiry dates.

It is important that proper sized syringes are chosen to ensure the correct volume is accurately drawn up. Refer to the Canadian Immunization Guide, Table 3: Needle selection guidelines for assistance in selecting appropriate needle length and gauge. Safety engineered needles must be used as required under O. Reg. 474/07 made under the Occupational Health and Safety Act.

Information on vaccine storage, stability and disposal can be found in the COVID-19: Vaccine Storage and Handling Guidance document.
Appendix B: Moderna COVID-19 Vaccine

Considerations for Administration

In alignment with NACI’s recommendations, the Ministry of Health has made a **preferential recommendation for the use of Pfizer-BioNTech COVID-19 vaccine for individuals 5-29 years of age if receiving a primary series dose, or 5-17 years of age if receiving a booster dose.** This recommendation stems from an observed increase in the number of reports of myocarditis/pericarditis following vaccination with Moderna relative to Pfizer-BioNTech in adolescents and young adults, particularly among males, in Ontario, Canada, and internationally. Post-market surveillance safety data to date have not shown product-specific differences in the risks of myocarditis and/or pericarditis after a booster dose of an mRNA COVID-19 vaccine. Therefore adults 18 years of age and older can receive a booster dose with any available mRNA COVID-19 vaccine for which they are currently eligible.

Currently, the Moderna (25 mcg) COVID-19 vaccine is the only authorized vaccine for children 6 months to under 5 years of age. Based on Phase 2/3 clinical trial data, humoral immune responses were similar compared to young adults, the vaccine was well tolerated with no safety signals, and reactogenicity was congruent with other recommended vaccines in this age category. As real-world evidence on the use of this vaccine in this age group is not available yet, and the clinical trial size was limited, the risk of rare adverse effects such as myocarditis and/or pericarditis is unknown. A primary series of two doses of Moderna (25 mcg) COVID-19 vaccine may be offered to children 6 months to 5 years of age who do not have contraindications to the vaccine, with a recommended interval of 56 days (2 months) between the first and second dose. Children who have underlying medical conditions are strongly encouraged to complete the entire series. If the child is immunocompromised, they should complete a three dose primary series.

Children who are 5 years of age are eligible for both the Moderna (25 mcg) or Pfizer-BioNTech (10 mcg) vaccine. The use of Pfizer-BioNTech vaccine (10 mcg) is preferred to the Moderna (25 mcg) for those 5 years of age. However, per NACI, Moderna (25 mcg) may be offered to children who are 5 years of age as an alternative to the Pfizer-BioNTech vaccine (10 mcg), with informed consent and discussion of risks and benefits with the child’s healthcare provider. For children who have received a Moderna (25 mcg) dose and turn 5 prior to completing their primary series are recommended to receive Moderna (25 mcg) to complete their primary series.
For children who have received a Moderna (25 mcg) dose and turn 6 prior to completing their primary series are recommended to receive Moderna (50 mcg) to complete their primary series. If the primary series was completed with Moderna (25 mcg) or with Pfizer-BioNTech (10 mcg), the dose should be considered valid and the series complete.

The same mRNA COVID-19 vaccine product should be offered for the subsequent dose in a primary series started with a specific mRNA COVID-19 vaccine. However, in following the established guidance on interchangeability of mRNA COVID-19 vaccines, when the same mRNA vaccine product is not readily available, is unknown, or is no longer authorized for the age group (e.g., once a child has turned 6 years of age), another mRNA COVID-19 vaccine product recommended in that age group can be considered interchangeable.

Indirect data from adult populations (≥18 years of age) suggests Moderna (100 mcg) may result in higher vaccine effectiveness after a 2-dose primary series compared to Pfizer-BioNTech (30 mcg) and is associated with a higher seroconversion rate among adult immunocompromised patients (NACI, 2022). Given this potential benefit, administration of the Moderna (50 mcg) vaccine as a 3-dose primary series may be considered for some moderately to severely immunocompromised individuals 6 to 11 years of age, as outlined in the product monograph.

Should individuals aged 5 to 29 years of age request Moderna for their primary series when it is not the preferred product, they can access it with informed consent, which should include awareness of the possible elevated risk of myocarditis/pericarditis. Although risk of myocarditis/pericarditis with the Moderna in children 5 to 11 years of age is unknown, with a primary series in adolescents and young adults the rare risk of myocarditis/pericarditis with Moderna (100 mcg) was higher than with Pfizer-BioNTech (30 mcg). Children 5 years of age should receive the 25 mcg dose of the Moderna vaccine, children 6 to 11 years of age should receive the 50 mcg dose of the Moderna vaccine, whereas adolescents and adults 12 years of age and older should continue to receive the 100 mcg dose of the Moderna vaccine as part of their primary series.

**Moderna Spikevax Bivalent (50 mcg)** is the first bivalent, Omicron containing mRNA COVID-19 vaccine authorized by Health Canada for use as a booster dose in individuals ≥ 18 years of age. This new formulation contains 25 mcg of mRNA encoding for the original SARS-CoV-2 virus and 25 mcg of mRNA encoding the Omicron BA.1 variant. When given as a second booster dose, the Moderna Bivalent (50 mcg) demonstrated a higher neutralizing antibody response against the original strain, Omicron BA.1 and Omicron BA.4 and BA.5 among individuals with and without
prior infection when compared to a second booster dose of the original Moderna (50 mcg). This effect was consistent across individuals from various age groups (18 years and older).

Clinical trial data has shown that when used as a second booster for individuals ≥ 18 years of age, the Moderna Bivalent (50 mcg) had a similar reactogenicity profile as that of the original Moderna (50 mcg). The frequency of adverse events following administration of Moderna Bivalent (50 mcg) as a second booster was similar or lower compared to that of a first booster dose of Moderna original (50 mcg) and second dose of Moderna original primary series (100 mcg). There were no reports of vaccine-related cases of myocarditis, pericarditis or deaths during the study period. No new safety signals were identified with the Moderna Bivalent (50 mcg). Given the limited number of study participants, NACI will continue to monitor post-market surveillance data.

**Warnings & Precautions**

**Myocarditis & Pericarditis**

See section above on myocarditis and pericarditis and the Canadian Immunization Guide for information.

**Multi-Inflammatory Syndrome in Children or in Adults (MIS-C/A) following vaccination with an mRNA COVID-19 vaccine**

See section above on MIS-C/A and the Canadian Immunization Guide for information.

**Bell’s palsy following vaccination with an mRNA COVID-19 vaccine**

See section above on Bell’s palsy following vaccination with an mRNA COVID-19 vaccine and the Canadian Immunization Guide for information.

**Allergies**

See the COVID-19 Vaccine: Canadian Immunization Guide for information on vaccination for all individuals with allergies (including those with allergic reactions to previous doses of any COVID-19 vaccine, or vaccine components).

**Side effects**

The Moderna COVID-19 vaccine, like medicines and other vaccines can cause side effects. In clinical trials, most of the side effects experienced were mild to moderate and on average did not last longer than three days. Please see the product monograph for a complete list of reported side effects.
Vaccine Preparation

Detailed information on vaccine preparation and transport can be found in the product monograph and the COVID-19: Vaccine Storage and Handling Guidance.

- For guidance on what to do when there is leftover solution in the vial or if more than the stated number of doses can be obtained, please see the COVID-19: Vaccine Storage and Handling Guidance document.

Vaccine Administration

See the Moderna product monograph for step-by-step directions for administration (vial and dose verification, thawing prior to dilution, dilution, preparation).

It is important that proper sized syringes are chosen to ensure the correct volume is accurately drawn up. Refer to the Canadian Immunization Guide, Table 3: Needle selection guidelines for assistance in selecting appropriate needle length and gauge. Safety engineered needles must be used as required under O. Reg. 474/07 made under the Occupational Health and Safety Act.

Information on vaccine storage, stability and disposal can be found in the COVID-19: Vaccine Storage and Handling Guidance document.
Appendix C: AstraZeneca COVID-19 Vaccine

Considerations for Administration

As per NACI, the AstraZeneca COVID-19 vaccine may be offered to individuals who have contraindications to all other authorized COVID-19 vaccines. Individuals that received AstraZeneca COVID-19 vaccine for their first and second doses are recommended to receive an mRNA COVID-19 vaccine for their booster dose(s).

- In Ontario, viral vector COVID-19 vaccines are currently only available to individuals with contraindications to all other authorized COVID-19 vaccines as identified by an appropriate physician or nurse practitioner.

- Regardless of which product is offered, it is important that individuals receive all recommended doses (including booster doses) of a COVID-19 vaccine.

- For guidance on booster doses of a COVID-19 vaccine, please consult the COVID-19 Vaccine Booster Dose Recommendations.

Contraindications

AstraZeneca COVID-19 vaccine is contraindicated in individuals who have experienced venous and/or arterial thrombosis with thrombocytopenia following vaccination with a viral vector COVID-19 vaccine.

As per NACI, the AstraZeneca COVID-19 vaccine is contraindicated in individuals who have previously experienced episodes of capillary leak syndrome (CLS) (related or not to vaccination).

Warnings & Precautions

As per NACI, anyone receiving any authorized viral vector COVID-19 vaccine should be informed of the risks associated with viral vector vaccines including Thrombosis with Thrombocytopenia Syndrome (TTS) including Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), Capillary Leak Syndrome (CLS), Immune thrombocytopenia (ITP), Venous thromboembolism (VTE) and Guillain-Barré syndrome (GBS) following viral vector COVID-19 vaccines (NACI, 2022) and be advised to seek medical attention if they develop signs and symptoms suggestive of these conditions.

See the COVID-19 Vaccine: Canadian Immunization Guide for more information on precautions and contraindications for the AstraZeneca COVID-19 vaccine.
Allergies

See the [COVID-19 Vaccine: Canadian Immunization Guide](#) for information on vaccination for all individuals with allergies (including those with allergic reactions to previous doses of any COVID-19 vaccine, or vaccine components).

Side Effects

The AstraZeneca COVID-19 vaccine, like medicines and other vaccines can cause side effects. In clinical trials, most of the side effects experienced were mild to moderate and on average resolved within a few days. Please see the product monograph for [AstraZeneca COVID-19 vaccine](#) for a complete list of reported side effects/adverse reactions.

Vaccine Preparation & Administration

- See the [AstraZeneca product monograph](#) for step-by-step directions for administration (vial and dose verification, thawing prior to dilution, dilution, preparation) and information on packaging types and expiry dates.

- It is important that proper sized syringes are chosen to ensure the correct volume is accurately drawn up. Refer to the [Canadian Immunization Guide, Table 3: Needle selection guidelines](#) for assistance in selecting appropriate needle length and gauge. Safety engineered needles must be used as required under O. Reg. 474/07 made under the Occupational Health and Safety Act.

Information on vaccine storage, stability and disposal can be found in the [COVID-19: Vaccine Storage and Handling Guidance](#) document.
Appendix D: Janssen Jcovden COVID-19 Vaccine

Considerations for Administration
As per NACI, the Janssen COVID-19 vaccine may be offered to individuals who have contraindications to all other authorized COVID-19 vaccines, as identified by an appropriate physician or nurse practitioner.

- Regardless of which product is offered, it is important that individuals receive all recommended doses (including booster doses) of a COVID-19 vaccine.
- Individuals that received Janssen COVID-19 vaccine for their first dose are recommended to receive an mRNA COVID-19 vaccine for their booster dose(s). For guidance for booster doses of a COVID-19 vaccine, please consult the COVID-19 Vaccine Booster Dose Recommendations.

Contraindications
The Janssen COVID-19 vaccine is contraindicated in individuals who have experienced venous and/or arterial thrombosis with thrombocytopenia following vaccination with a viral vector COVID-19 vaccine. Individuals with a history of capillary leak syndrome (related or not to previous vaccination) should not receive the Janssen COVID-19 vaccine, as per NACI.

Warnings & Precautions
As per NACI, anyone receiving any authorized viral vector COVID-19 vaccine should be informed of the risks associated with viral vector vaccines: Thrombosis with Thrombocytopenia Syndrome (TTS) including Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), Capillary Leak Syndrome (CLS), Immune thrombocytopenia (ITP), Venous thromboembolism (VTE) and Guillain-Barré syndrome (GBS) following viral vector COVID-19 vaccines (NACI, 2022) and be advised to seek medical attention if they develop signs and symptoms suggestive of these conditions.

See the COVID-19 Vaccine: Canadian Immunization Guide for more information on precautions and contraindications for the Janssen COVID-19 vaccine.

Allergies
See the COVID-19 Vaccine: Canadian Immunization Guide for information on vaccination for all individuals with allergies (including those with allergic reactions to previous doses of any COVID-19 vaccine, or vaccine components).
Side effects

The Janssen COVID-19 vaccines, like medicines and other vaccines can cause side effects. In clinical trials, most of the side effects experienced were mild to moderate and on average did not last longer than three days. Please see the product monographs for Janssen COVID-19 vaccine for a complete list of reported side effects/ adverse reactions.

Vaccine Preparation & Administration

This is a single dose vaccine; protection will be attained only after 2 weeks following administration of the vaccine.

- See the Janssen product monograph for step-by-step directions for administration (vial and dose verification, thawing prior to dilution, dilution, preparation) and information on packaging types and expiry dates.

- It is important that proper sized syringes are chosen to ensure the correct volume is accurately drawn up. Refer to the Canadian Immunization Guide, Table 3: Needle selection guidelines for assistance in selecting appropriate needle length and gauge. Safety engineered needles must be used as required under O. Reg. 474/07 made under the Occupational Health and Safety Act.

Information on vaccine storage, stability and disposal can be found in the COVID-19: Vaccine Storage and Handling Guidance document.
Appendix E: Novavax COVID-19 Vaccine

Considerations for Administration

Health Canada authorized the Novavax COVID-19 vaccine for use in a primary series in people 18 years of age and over on February 17, 2022. The Novavax vaccine is the first recombinant protein subunit COVID-19 vaccine authorized for use in Canada.

Novavax consists of a purified full-length SARS-CoV-2 recombinant spike (S) protein nanoparticle administered as a co-formulation with the adjuvant Matrix-M™. Matrix-M™ is a novel saponin-based adjuvant that facilitates activation of the cells of the body’s innate immune system, which enhances the magnitude and duration of the S protein-specific immune response. Matrix-M™ has been used in Novavax clinical trials and in pre-licensure studies targeting other pathogens, but has not previously been used in any licensed vaccine.

Clinical trial data available to date show that the Novavax vaccine is highly efficacious in preventing confirmed symptomatic COVID-19 disease in the short term. However, the duration of protection is not yet known and there is currently no data on the efficacy or effectiveness of the vaccine against the Delta or Omicron variants, as clinical trials were conducted before the emergence of these variants.

The safety and efficacy of Novavax has not been established in the following populations: individuals previously infected with SARS-CoV-2; individuals who are immunocompromised due to disease or treatment; individuals who are pregnant or breastfeeding; individuals who have an autoimmune condition.

NACI continues to preferentially recommend the use of mRNA COVID-19 vaccines due to the excellent protection they provide against severe illness and hospitalization, and their well-known safety profiles. The Novavax vaccine is a new COVID-19 vaccine option that may be offered to individuals in the authorized age group who are not able, due to contraindications, or not willing to receive an mRNA COVID-19 vaccine.

A primary series of the Novavax COVID-19 vaccine is currently considered to be two doses. People may receive two doses of the Novavax vaccine (homologous series) or a mixed (heterologous) primary series (one dose of the Novavax vaccine and one dose of another COVID-19 vaccine). If receiving a mixed primary series with the Novavax vaccine, informed consent should include a discussion of the benefits and potential risks given the currently limited data on the effectiveness and safety of mixed schedules with the Novavax vaccine.
The Novavax COVID-19 vaccine may be offered as a booster dose to people who are not willing or not able to receive an mRNA vaccine, regardless of which COVID-19 vaccines were received in the primary series. This recommendation is off-label, as the Novavax COVID-19 vaccine is not currently authorized for use by Health Canada as a booster dose in Canada. Informed consent should include a discussion of the long-term effectiveness and safety data that is available for the mRNA vaccine products as compared to the other authorized COVID-19 vaccines and the benefits and potential risks of the use of the Novavax vaccine as a booster dose, including the off-label status of this recommendation.

For individuals with serious polyethylene glycol (PEG) allergy or previous serious allergic reaction to an mRNA vaccine precluding vaccination with mRNA vaccines, Novavax may be the preferred product for vaccination, based on consultation with an allergist or other appropriate physician or nurse practitioner.

**Warnings & Precautions**

As per NACI, individuals who refuse mRNA vaccines should be made aware of the long term effectiveness and safety data that are available for mRNA products as compared to other vaccines as part of informed consent before offering Novavax.

At the time of approval, there are no known serious warnings or precautions associated with the Novavax vaccine.

**Allergies**

See the COVID-19 Vaccine: Canadian Immunization Guide for information on vaccination for all individuals with allergies (including those with allergic reactions to previous doses of any COVID-19 vaccine, or vaccine components).

**Side effects**

The Novavax COVID-19 vaccine, like medicines and other vaccines, can cause side effects. In clinical trials, most of the side effects experienced were mild to moderate and generally, resolved in 1-2 days. They occurred more frequently after the second dose and were more common in adults 18 to 64 years of age compared to older adults ≥ 65 years old. Please see the product monographs for Novavax COVID-19 vaccine for a complete list of reported side effects/ adverse reactions.

**Vaccine Preparation & Administration**

See the Novavax product monograph for step-by-step directions for administration (vial and dose verification, thawing prior to dilution, dilution, preparation) and information on packaging types and expiry dates.
It is important that proper sized syringes are chosen to ensure the correct volume is accurately drawn up. Refer to the Canadian Immunization Guide, Table 3: Needle selection guidelines for assistance in selecting appropriate needle length and gauge. Safety engineered needles must be used as required under O. Reg. 474/07 made under the Occupational Health and Safety Act.

Information on vaccine storage, stability and disposal can be found in the COVID-19: Vaccine Storage and Handling Guidance document.
Appendix F: Medicago COVID-19 Vaccine

Considerations for Administration


The Medicago COVID-19 vaccine is an adjuvanted vaccine consisting of recombinant SARS-CoV-2 spike glycoproteins stabilized in the prefusion conformation that are produced by transient expression in *Nicotiana benthamiana* plants and become membrane imbedded in self-assembled enveloped virus-like particles (VLP).

Clinical trial data available to date show that the Medicago vaccine is efficacious in preventing confirmed symptomatic COVID-19 disease in the short term. However, the duration of protection is not yet known and there is currently no data on the efficacy or effectiveness of the vaccine against the Omicron variant, as clinical trials were conducted before the emergence of the Omicron variant.

The safety and efficacy of Medicago has not been established in the following populations: individuals previously infected with SARS-CoV-2; individuals who are immunocompromised due to disease or treatment; individuals who are pregnant or breastfeeding; individuals who have an autoimmune condition.

NACI continues to preferentially recommend the use of mRNA COVID-19 vaccines for most people due to the excellent protection they provide against severe illness and hospitalization, and their well-known safety profiles. The Medicago vaccine is a new COVID-19 vaccine option that may be offered to individuals who are not able to, due to contraindications, or not willing to receive an mRNA COVID-19 vaccine.

A primary series of the Medicago COVID-19 vaccine is currently considered to be two doses. People may receive two doses of the Medicago vaccine (homologous series) or a mixed (heterologous) primary series (one dose of the Medicago vaccine and one dose of another COVID-19 vaccine). If receiving a mixed primary series with the Medicago vaccine, informed consent should include a discussion of the benefits and potential risks given the absence of data on the effectiveness and safety of mixed schedules with the Medicago vaccine.

Medicago is not currently authorized for use as a booster dose in Canada. Clinical trials of a booster dose of this vaccine are planned for Spring 2022. At the time of publication, there are no data available on the use of Medicago as a booster dose in either a homologous or heterologous schedule. Informed consent when administering a Medicago primary series should therefore include mention that this
vaccine is not currently authorized for use as a booster dose in Canada. NACI will assess evidence on the use of Medicago vaccine as a booster dose as information becomes available and provide additional guidance as needed. See the COVID-19 Vaccine Booster Dose Recommendations for more information.

Warnings & Precautions

As per NACI, individuals who are not willing to receive an mRNA vaccine should be made aware of the long term effectiveness and safety data that are available for the mRNA products as compared to Medicago as part of informed consent before offering Medicago, including a discussion of the benefits and risks given the limited data available on administration of the Medicago.

At the time of approval, there are no known serious warnings or precautions associated with the Medicago vaccine.

Allergies

See the COVID-19 Vaccine: Canadian Immunization Guide for information on vaccination for all individuals with allergies (including those with allergic reactions to previous doses of any COVID-19 vaccine, or vaccine components).

Side effects

The Medicago COVID-19 vaccine, like medicines and other vaccines, can cause side effects. In clinical trials, most of the side effects experienced were mild to moderate and generally, resolved in 1-2 days. Please see the product monograph for Medicago COVID-19 vaccine for a complete list of reported side effects/ adverse reactions.

Vaccine Preparation & Administration

See the Medicago product monograph for step-by-step directions for administration (vial and dose verification, thawing prior to dilution, dilution, preparation) and information on packaging types and expiry dates.

It is important that proper sized syringes are chosen to ensure the correct volume is accurately drawn up. Refer to the Canadian Immunization Guide, Table 3: Needle selection guidelines for assistance in selecting appropriate needle length and gauge. Safety engineered needles must be used as required under O. Reg. 474/07 made under the Occupational Health and Safety Act.

Information on vaccine storage, stability and disposal can be found in the COVID-19: Vaccine Storage and Handling Guidance document.
Appendix G: List of Immunosuppressive Medications

‘This list may not be comprehensive: health care providers may identify patients on other medications that are significantly immunosuppressive. Prescriptions for the below immunosuppressant medications can be presented for additional doses as needed. If an individual presents a prescription of a medication that is not listed in Table 1, they should be directed to their health care provider to receive a referral form/letter for a third and any subsequent dose(s) of a COVID-19 vaccine.

<table>
<thead>
<tr>
<th>Class</th>
<th>Generic Name(s)</th>
<th>Brand Name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroids (&gt;20 mg per day of prednisone or equivalent for at least 2 weeks)(^{10})</td>
<td>• Prednisone</td>
<td>• Decadron</td>
</tr>
<tr>
<td></td>
<td>• dexamethasone</td>
<td>• DepoMedrol</td>
</tr>
<tr>
<td></td>
<td>• methylprednisolone</td>
<td>• SoluMedrol</td>
</tr>
<tr>
<td></td>
<td>• methylprednisolone</td>
<td>• Medrol</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>• cyclophosphamide</td>
<td>• Procytox</td>
</tr>
<tr>
<td></td>
<td>• leflunomide</td>
<td>• Arava</td>
</tr>
<tr>
<td></td>
<td>• methotrexate</td>
<td>• Trexall</td>
</tr>
<tr>
<td></td>
<td>• methotrexate</td>
<td>• Metoject</td>
</tr>
<tr>
<td></td>
<td>• azathioprine</td>
<td>• Otrexup</td>
</tr>
<tr>
<td></td>
<td>• 6-mercaptopurine (6-MP)</td>
<td>• Rasuvo</td>
</tr>
<tr>
<td></td>
<td>• mycophenolic acid</td>
<td>• Rheumatrex</td>
</tr>
<tr>
<td></td>
<td>• mycophenolate mofetil</td>
<td>• Imuran</td>
</tr>
<tr>
<td></td>
<td>• mycophenolate mofetil</td>
<td>• Purinethol</td>
</tr>
<tr>
<td></td>
<td>• Cellcept</td>
<td>• Myfortic</td>
</tr>
</tbody>
</table>

\(^{10}\) As the dosing information may not be included on the patient’s prescription, confirmation of the dosage from the individual presenting their prescription is sufficient. Equivalent steroid dose (prednisone 20 mg = prednisolone 20 mg = methylprednisolone 16 mg = hydrocortisone 80 mg = dexamethasone 3 mg)
<table>
<thead>
<tr>
<th>Class</th>
<th>Generic Name(s)</th>
<th>Brand Name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcineurin inhibitors/mTOR kinase inhibitor</td>
<td>tacrolimus</td>
<td>Prograf, Advagraf, Envarsus PA</td>
</tr>
<tr>
<td></td>
<td>cyclosporine</td>
<td>Neoral, Gengraf, Sandimmune</td>
</tr>
<tr>
<td></td>
<td>sirolimus</td>
<td>Rapamune</td>
</tr>
<tr>
<td>JAK (Janus kinase) inhibitors</td>
<td>baricitinib</td>
<td>Olumiant</td>
</tr>
<tr>
<td></td>
<td>tofacitinib</td>
<td>Xeljanz</td>
</tr>
<tr>
<td></td>
<td>upadacitinib</td>
<td>Rinvoq</td>
</tr>
<tr>
<td>Anti-TNF (tumor necrosis factor)</td>
<td>adalimumab</td>
<td>Humira, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio</td>
</tr>
<tr>
<td></td>
<td>golimumab</td>
<td>Simponi</td>
</tr>
<tr>
<td></td>
<td>certolizumab pegol</td>
<td>Cimzia</td>
</tr>
<tr>
<td></td>
<td>etanercept</td>
<td>Enbrel, Brenzys, Erelzi</td>
</tr>
<tr>
<td></td>
<td>infliximab</td>
<td>Remicade, Avsola, Inflectra, Remsima, Renflexis</td>
</tr>
<tr>
<td>Anti-Inflammatory</td>
<td>Sulfasalazine</td>
<td>Salazopyrin, Azulfidine</td>
</tr>
<tr>
<td></td>
<td>5-Aminosalicylic Acid (ASA)/mesalamine</td>
<td>Pentasa</td>
</tr>
<tr>
<td>Class</td>
<td>Generic Name(s)</td>
<td>Brand Name(s)</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Anti-CD20</td>
<td>• Rituximab</td>
<td>• Rituxan</td>
</tr>
<tr>
<td></td>
<td>• ocrelizumab</td>
<td>• Ocrevus</td>
</tr>
<tr>
<td></td>
<td>• ofatumumab</td>
<td>• Kesimpta</td>
</tr>
<tr>
<td>IL-1 RA (interleukin-1 receptor antagonist)</td>
<td>• anakinra</td>
<td>• Kineret</td>
</tr>
<tr>
<td></td>
<td>• canakinumab</td>
<td>• Ilaris</td>
</tr>
<tr>
<td>Anti-IL6</td>
<td>• tocilizumab</td>
<td>• Actemra</td>
</tr>
<tr>
<td></td>
<td>• sarilumab</td>
<td>• Kevzara</td>
</tr>
<tr>
<td>Anti-IL12/IL23</td>
<td>• ustekinumab</td>
<td>• Stelara</td>
</tr>
<tr>
<td>Anti-IL17</td>
<td>• secukinumab</td>
<td>• Cosentyx</td>
</tr>
<tr>
<td></td>
<td>• ixekizumab</td>
<td>• Taltz</td>
</tr>
<tr>
<td>Anti-IL17R</td>
<td>• brodalumab</td>
<td>• Siliq</td>
</tr>
<tr>
<td>Anti-BLYS</td>
<td>• belimumab</td>
<td>• Benlysta</td>
</tr>
<tr>
<td>Anti-IL23</td>
<td>• guselkumab</td>
<td>• Tremfya</td>
</tr>
<tr>
<td>Selective T-cell costimulation blocker</td>
<td>• abatacept</td>
<td>• Orencia</td>
</tr>
<tr>
<td>S1PR (sphingosine 1-phosphate receptor) agonist</td>
<td>• fingolimod</td>
<td>• Gilenya</td>
</tr>
<tr>
<td></td>
<td>• siponimod</td>
<td>• Mayzent</td>
</tr>
<tr>
<td></td>
<td>• ozanimod</td>
<td>• Zeposia</td>
</tr>
<tr>
<td>Phosphodiesterase inhibitors</td>
<td>• Apremilast</td>
<td>• Otezla</td>
</tr>
<tr>
<td>Anti-integrin</td>
<td>• vedolizumab</td>
<td>• Entyvio</td>
</tr>
</tbody>
</table>